Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. is set to launch a crucial Phase III trial for its prostate cancer diagnostic agent, 64Cu-SAR-bisPSMA, following promising discussions with the U.S. FDA. The trial, named AMPLIFY, will evaluate the agent’s efficacy in detecting recurrent prostate cancer in a non-randomised, single-arm study of approximately 220 patients. This follows successful prior trials which demonstrated significant improvements over standard imaging agents, potentially offering enhanced detection capabilities and improved treatment outcomes for patients.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.